GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Oct. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC), Blueprint Genetics, and Foundation Fighting Blindness , announce today that AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus
- Planned Phase 2/3 trial expected to include approximately 60 patients and a responder analysis based on at least 7 decibel improvement in visual sensitivity in at least 5 loci across two active dose groups and one control group - - Data from Group 5 supports use of higher dose level in Phase 2/3
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
Preclinical studies validate the transgene and dosing used in the ongoing Phase 1/2 clinical trial in patients with XLRP due to mutations in the RPGR gene GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a
Patient Advisory Council to include advocates from the inherited retinal diseases global community New Patient Advisory Council to focus initially on Company ’ s clinical stage programs for X-linked retinitis pigmentosa (XLRP) GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Aug.
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
FDA feedback allows for forward program development Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinical development GAINESVILLE, Fla. and CAMBRIDGE, Mass. , July 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic
